Day Return
YTD Return
1-Year Return
3-Year Return
5-Year Return
Note: Sector performance is calculated based on the previous closing price of all sector constituents
Industries in This Sector
Select an Industry for a Visual Breakdown
| Industry | Market Weight | YTD Return | |
|---|---|---|---|
| All Industries | 100.00% | 4.40% | |
| Drug Manufacturers - General | 34.14% | 10.39% | |
| Healthcare Plans | 13.03% | -5.17% | |
| Medical Devices | 12.73% | 4.62% | |
| Diagnostics & Research | 11.65% | 6.43% | |
| Biotechnology | 11.61% | -1.25% | |
| Medical Instruments & Supplies | 6.65% | 4.76% | |
| Medical Care Facilities | 2.92% | 12.37% | |
| Drug Manufacturers - Specialty & Generic | 2.73% | -4.69% | |
| Medical Distribution | 2.32% | 8.08% | |
| Health Information Services | 2.01% | 3.09% | |
| Pharmaceutical Retailers | 0.21% | -38.15% | |
Note: Percentage % data on heatmap indicates Day Return
All Industries
-
Largest Companies in This Sector
|
Name
|
Last Price
|
1Y Target Est.
|
Market Weight
|
Market Cap
|
Day Change %
|
YTD Return
|
Avg. Analyst Rating
|
|---|---|---|---|---|---|---|---|
| 807.43 | 859.23 | 11.83% |
|
|
|
Buy
|
|
| 508.17 | 567.48 | 7.21% |
|
|
|
Buy
|
|
| 146.97 | 159.74 | 5.45% |
|
|
|
Buy
|
|
| 129.49 | 130.79 | 5.06% |
|
|
|
Buy
|
|
| 157.06 | 183.11 | 4.28% |
|
|
|
Buy
|
|
| 584.05 | 624.17 | 3.44% |
|
|
|
Buy
|
|
| 262.78 | 271.39 | 3.00% |
|
|
|
Buy
|
|
| 103.95 | 116.34 | 2.79% |
|
|
|
Buy
|
|
| 305.84 | 294.40 | 2.53% |
|
|
|
Buy
|
|
| 28.88 | 29.87 | 2.52% |
|
|
|
Buy
|
Investing in the Healthcare Sector
Start Investing in the Healthcare Sector Through These ETFs and Mutual Funds
ETF Opportunities
|
Name
|
Last Price
|
Net Assets
|
Expense Ratio
|
YTD Return
|
|---|---|---|---|---|
| 144.42 | 37.936B | 0.09% |
|
|
| 263.51 | 20.002B | 0.10% |
|
|
| 135.67 | 6.991B | 0.45% |
|
|
| 88.83 | 6.358B | 0.35% |
|
|
| 56.07 | 5.241B | 0.40% |
|
Mutual Fund Opportunities
|
Name
|
Last Price
|
Net Assets
|
Expense Ratio
|
YTD Return
|
|---|---|---|---|---|
| 215.01 | 45.706B | 0.29% |
|
|
| 90.66 | 45.706B | 0.29% |
|
|
| 131.85 | 20.002B | 0.10% |
|
|
| 92.74 | 15.399B | 0.80% |
|
|
| 92.78 | 14.487B | 0.80% |
|
Healthcare Research
Discover the Latest Analyst and Technical Research for This Sector
-
Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover
In this edition, P&C insurers overvalued despite tailwind; prospects and caveats for P&C insurers; breaking down the Live Nation breakup sought by DOJ; and VF, Evotec SE ADR, and Stericycle.
-
Analyst Report: Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
RatingPrice Target -
Analyst Report: Novo Nordisk A/S
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
RatingPrice Target -
Analyst Report: Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
RatingPrice Target
